Take degenerative disc disease, for example. When you take a fibroblast cell and you put it into the nucleus of the disc, you ...

Surgifort is the first FDA-approved human milk-based fortifier specifically designed for term infants recovering from ...

Daniel Vitt, CEO, Immunic Therapeutics, discusses how the safety and tolerabilities results from Phase I trials for IMU-856 influences further studies for gastrointestinal diseases moving forward.

In this Pharmaceutical Executive video interview, Jen Butler, Chief Commercial Officer of Pleio, discusses the significant threat of misinformation to public health and how emotional appeal plays a ...

Daniel Vitt, CEO, Immunic Therapeutics, discusses how IMU-856 could support the challenges of gluten-free diets and cross-contamination risks for celiac disease.

Keytruda demonstrated a statistically significant and clinically meaningful improvement in event-free survival and major ...

Aspargo Labs uses a proprietary technology platform to reformulate oral medication to liquid doses. CEO and chairman Michael ...

Vaxitek HVT+IBD+H5 integrates COBRA technology to address the ongoing viral evolution challenges of avian influenza, as well ...

The BrainSense adaptive deep brain stimulation system personalizes therapy by dynamically adjusting stimulation based on real ...

Biopharmas and global agencies are now prioritizing initiatives and innovations to drive speed across product development ...

Unconfirmed reports suggest that a popular flu vaccine educational campaign has come to an end.

John Arena, interim president of global pharma services at Cencora, discusses how new technologies are shortening timelines.